EyePoint, Inc.

Item 1.01 Entry into a Material Definitive Agreement. On July 17, 2026 (the “Effective Date”), EyePoint, Inc. (the “Company”) entered into a settlement agreement (the “Settlement Agreement”) with the United States of America, acting through the U.S. Department of Justice (“DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human Services (“OIG-HHS”) and the Defense Health Agency (“DHA”), acting on behalf of the TRICARE Program, and the relator named therein. The Settlement Agreement settles potential claims against the Company related to alleged civil violations of the False Claims Act, the Civil Monetary Penalties Law, the Administrative False Claims Act and other legal theories pertaining to certain of the Company’s sales, marketing and promotional practices, including sampling practices, as pertain to DEXYCU®, which the Company commercialized from 2019 to 2023 (as further described in the Settlement Agreement, the “Covered Conduct”). The Settlement Agreement avoids the uncertainty and expense of protracted litigation and does not constitute an admission of liability by the Company. Pursuant to the Settlement Agreement, the Company agreed, among other things, to pay a settlement amount of $4,678,981.86, plus interest at a rate of 4.25% per annum from January 28, 2026 (the “Settlement Payment”). The Settlement Payment consists of (i) $4,657,463.18 (plus interest) to be paid to the United States and (ii) $21,518.68 (plus interest) to be paid to certain participating states, in each case payable no later than 14 days after the Effective Date. In addition, the Company agreed to pay $166,500 for attorneys’ fees and costs to relator’s counsel no later than 60 days after the Effective Date. The Company currently intends to use cash on hand to pay such amounts. Conditioned upon payment of the Settlement Payment, the DOJ, OIG-HHS, DHA and the relator have agreed to release the Company and its subsidiaries from any civil or administrative monetary liability arising from the Covered Conduct, and the DOJ and the relator have agreed to dismiss the civil action filed by the relator. In connection with the Settlement Agreement, on July 13, 2026, the Company entered into a Corporate Integrity Agreement (the “Corporate Integrity Agreement”) with OIG-HHS. The Corporate Integrity Agreement requires the Company to, among other things, maintain a Compliance Officer, a Compliance Committee, and board review and oversight of certain federal healthcare compliance matters, compliance programs and disclosure and notification programs; retain a board compliance expert; provide management certifications and compliance training and education; establish written compliance policies and procedures to meet federal health care program requirements; create procedures designed to ensure compliance with federal healthcare programs; engage an independent review organization; screen employees to ensure they are not barred from participating in federal health care programs; and implement a risk assessment and internal review process. In exchange, OIG-HHS agreed not to seek the exclusion of the Company from participation in Medicare, Medicaid, or other federal health care programs as a result of the Covered Conduct. The Company’s failure to comply with its obligations under the Corporate Integrity Agreement could result in monetary penalties or the Company being excluded from participating in federal health care programs. The Corporate Integrity Agreement has a term of five years, commencing on July 13, 2026. The foregoing descriptions of the Settlement Agreement and the Corporate Integrity Agreement are qualified by the full terms of those agreements, which are attached as Exhibits 10.1 and 10.2 hereto, respectively, and incorporated by reference herein.